AlphaTON Capital Corp. has executed a binding call option agreement granting Immunova, LLC the right to acquire its subsidiary iOx Therapeutics Limited, which develops liposomal iNKT agonists. Upon exercise of the option and completion of the acquisition, AlphaTON would receive an upfront cash payment, equity in the acquiring entity equal to 10% of its fully diluted shares, potential milestone payments exceeding $100 million, and single-digit royalties on future net sales. The option is subject to conditions including Immunova securing financing commitments, and the transaction is pending customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlphaTON Capital Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602171515PRIMZONEFULLFEED9656128) on February 17, 2026, and is solely responsible for the information contained therein.